Document made available to the pharmacist to communicate a drug interaction to the doctor.DOWNLOAD
Glecaprevir / Pibrentasvir may inhibit CYP 3A4 and OATP1B1 and increase the plasma concentration of Lovastatin.
P-gp and BCRP; OATP1B1/3 (glecaprevir)
P-gp, BCRP, OATP1B1/3; 3A4, 1A2 and UGT 1A1 (weak probably without clinical consequences)
3A4 (major); P-gp
2C9 and 2D6, 3A4 (weak); P-gp
Possible increased risk of HMG CoA inhibitor toxicity.
Increased risk of myopathy and rhabdomyolysis.
Avoid association. Choose an alternative.
Symptoms of toxicity associated with hypolipidemic agents : gastrointestinal effects, fatigue and muscular weaknesses, myalgias, muscular cramps, myopathies, rhabdomyolysis and myoglobinuria leading to renal insufficiency.
|± 0% *|
|+ 70% *|
Ref #3373 : * Lovastatin acid (metabolite) AUC +310% (4.1x) and Cmax +473% (5.7x).
No significant changes in glecaprevir or pibrentasvir concentrations.